Overview

Acute Myeloid Leukemia Market Introduction

Acute myeloid leukemia market is envisioned to value over US $ 1.5 billion by the end of 2027 and record at a CAGR of over 12% during the forecast period of 2020-2027.

Acute Myeloid Leukemia (AML) is a cancer of myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid build-up of abnormal white blood cells causes interference in the production of normal blood cells. Acute Myeloid Leukemia has a propensity to increase towards age. Replacement of bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells, etc. This causes symptoms such as fatigue, breathlessness, easy bruising and bleeding. The market driving factors for acute myeloid Leukemia are a rise in risk factors such as carcinogens, bold disorders, and genetics, etc.

According to the American Cancer Society, about 21,450 newly diagnosed cases are registered with a mortality rate of 50% in 2018. It mostly affects the adult population with a 5-year survival rate of 27%. Rapidly evolving scientific understanding of etiology led to the development of new therapeutic approaches for better management of AML. Further, increasing research activities led to the inclusion of immunotherapies in clinical practice and increased the life expectancy of AML patients. They are huge demand for effective management of disease due to highly unmet medical need and it offers monopolistic opportunities for manufacture. Further, supportive regulatory conditions like research incentives & fast approvals boosted the research activities in Acute Myeloid Leukemia area. Further, technological advancements led to the integration of gene therapies in the treatment and create opportunities for innovators.

North America market is expected to witness high market share in the global market due to supportive regulatory policies and high per capita healthcare expenditure. It is followed by the European region and it accounts a significant share in the global market due to well-established healthcare systems. Asia-Pacific regions are expected to witness a high market growth rate during the forecast period due to increasing awareness and changing healthcare policies. Latin America and Rest of the world market are expected to account a small fraction of market share due to lack of awareness.

Key Market Players include
Johnson & Johnson Private Limited, Pfizer Inc. Abbott, AstraZeneca, Bayer, Celgene Corporation, Ambit Biosciences Corporation, Cyclacel Pharmaceuticals Inc. Novartis AG and Sanofi.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Segmentation

By Drug Class

Tyrosine Kinase Inhibitors
Hedgehog Pathway Inhibitors
Topoisomerase 2 Inhibitors
Others

By End User

Hospital
Clinic
Others

By Region

North America
Latin America
Europe
Asia Pacific
Rest of the World

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the global Acute Myeloid Leukemia Market by Drug Class, by End User and by Region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies